DelNS1-2019-nCoV-RBD-OPT

{{short description|Vaccine against COVID-19}}

{{Use dmy dates|date=April 2021}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| Verifiedfields =

| verifiedrevid =

| drug_name =

| INN =

| type = vaccine

| image =

| alt =

| caption =

| target = SARS-CoV-2

| vaccine_type = viral

| pronounce =

| tradename = Pneucolin

| Drugs.com =

| MedlinePlus =

| licence_EU =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status =

| routes_of_administration = Intranasal

| CAS_number = 2696350–29-3

| CAS_number_Ref = {{cite web|url=https://www.wipo.int/edocs/pubdocs/en/wipo-pub-1075-en-covid-19-related-vaccines-and-therapeutics.pdf|title=Patent Landscape Report COVID-19-related vaccines and therapeutics}}

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = DelNS1-nCoV-RBD LAIV{{cite journal |title=A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04809389 |website=clinicaltrials.gov |date=29 April 2021 |publisher=United States National Library of Medicine |access-date=3 May 2021 }}

}}

{{COVID-19 pandemic sidebar}}

DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.{{cite news |title=China's nasal-spray COVID-19 vaccines undergoing clinical trials: official |url=http://www.xinhuanet.com/english/2021-06/11/c_1310003298.htm |access-date=10 July 2021 |publisher=Xinhua |date=11 June 2021}}{{cite web |title=A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1) |url=https://clinicaltrials.gov/ct2/show/NCT04809389 |website=chictr.org.cn |publisher=Chinese Clinical Trial Registry |access-date=24 March 2021 |url-status=live|archive-url=https://web.archive.org/web/20210407054232/https://clinicaltrials.gov/ct2/show/NCT04809389 |archive-date=7 April 2021 }}{{cite web |title=A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1) |url=http://www.chictr.org.cn/showprojen.aspx?proj=63754 |website=chictr.org.cn |publisher=Chinese Clinical Trial Registry |access-date=24 March 2021 |url-status=live|archive-url=https://web.archive.org/web/20201114133923/http://www.chictr.org.cn/showprojen.aspx?proj=63754 |archive-date=14 November 2020 }} It is administered as a single dose intranasal spray.{{cite journal | vauthors = Mi H, Chen Q, Lin H, He T, Zhang R, Ren S, Liu L, Wang J, Huang H, Wang M, Guo Z, Su C | title = Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study | journal = eClinicalMedicine | volume = 67 | issue = | pages = 102374 | date = January 2024 | pmid = 38169940 | pmc = 10758709 | doi = 10.1016/j.eclinm.2023.102374 }}

On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.{{cite web|url=http://www.nhc.gov.cn/xcs/zhengcwj/202212/acd8ba68d934488983909e81642dc337.shtml|title=关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知 | trans-title = Notice on the implementation plan for the second dose of new coronavirus vaccine booster vaccination |publisher=National Health Commission|date=2022-12-14|language=zh|accessdate=2022-12-14}}